News

What Becton Dickinson Stock's New U.S. Manufacturing Deal Means For Shareholders

Becton Dickinson has seen stronger performance in its high growth segments, supported by ongoing product development, clinical trial progress, and a major U.S. manufacturing agreement that was announced before the scheduled fiscal 2026 fourth quarter earnings release on 5 November. The combination of a new domestic manufacturing deal and clinical milestones reinforces Becton Dickinson’s push toward higher value medtech platforms with recurring demand exposure. We will now look at how Becton...

Yahoo·12:07BDX▼−0.7%

Becton Dickinson (BDX) Stock Trades Below Fair Value After A 40% Run

Becton Dickinson has delivered a strong share price run over the past year, which puts fresh focus on whether the current US$200.42 level is grounded in the cash it can generate. For anyone looking at the stock today, the central issue is how that recent performance lines up with the cash flow profile implied by its existing business. The share price return of 40.1% over the past year puts real pressure on the question of whether the valuation still lines up with the cash the business can...

Yahoo·11:18BDX▼−0.7%

Is Becton Dickinson (BDX) Fully Priced As Execution Improves Before Earnings?

Becton Dickinson (BDX) heads into its fourth quarter fiscal 2026 report with investors focused on recent execution improvements, progress in higher growth businesses, fresh product launches, and a major U.S. manufacturing agreement. Becton Dickinson’s recent news arrives after a strong run in the market, with the share price up 28.18% over the past 90 days and a 1-year total shareholder return of 40.14%. This points to building momentum as investors reassess its execution, pipeline progress,...

Yahoo·02:08BDX▼−0.7%

BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?

BD's 25.5% rally reflects stronger execution, portfolio reshaping, product innovation and U.S. manufacturing investments despite tariffs and cost pressures.

Yahoo·13:21BDX▼−0.7%

Can Boston Scientific Stock Bounce Off This Support Again?

For questions about this article or underlying research, email help@trefis.com.

Yahoo·21:29

Becton, Dickinson: Fundamentals Remain Solid, Trades Near Fair Value (Rating Downgrade)

Becton, Dickinson and Company stock surged 26% in 4 months as fundamentals rebounded; now near fair value at 15x P/E, rated HOLD. Click for more on BDX stock.

SeekingAlpha·07:45BDX▼−0.7%

Becton, Dickinson and Company Yields 2.4%: Is Its Valuation Finally Worth a Look?

Becton, Dickinson and Company (NYSE:BDX) has steady demand for its medical devices, together with a long history of paying dividends. The company’s product range includes medical essentials, connected care, biopharma systems, and devices for interventional procedures, which means it is exposed to spending on essential healthcare. Its decision to separate the Biosciences and Diagnostic Solutions […]

Yahoo·09:29BDX▼−0.7%

Becton Dickinson (BDX) Grew Revenue 5.4% While Earnings Fell 34.3%. Why Did Profit Fall So Much Further?

Becton, Dickinson and Company (NYSE:BDX) closed at $188.89 on October 12. The stock has returned over 21.5% during the last six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% for State Street SPDR S&P 500 ETF Trust. A medical device maker selling more and earning a third less has […]

Yahoo·15:29BDX▼−0.7%

Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Yahoo·11:10BDX▼−0.7%

Becton Dickinson (BDX) Posts Strong AGILITY Trial Results, Is The Stock Still Below Fair Value?

Becton Dickinson (BDX) just put fresh clinical data in front of investors. Nine-month results from the AGILITY trial for its Revello Vascular Covered Stent showed the study hit its primary endpoint in iliac artery disease. Recent clinical progress comes on top of a busy October for Becton Dickinson, including a new U.S. government manufacturing partnership and a leadership change in its Surgery unit, while a separate product recall underscored ongoing execution risk across the...

Yahoo·21:17BDX▼−0.7%

Will BD’s US$19 Billion U.S. Manufacturing Push and Tariff Relief Change Becton Dickinson's (BDX) Narrative

BD (Becton, Dickinson and Company) recently announced a landmark partnership with the U.S. government to expand domestic manufacturing of essential medical consumables, including a planned US$19.00 billion multi-year investment and a goal to produce all U.S. needles domestically using American-made steel while receiving relief from certain future Section 232 tariffs. This move materially deepens BD’s role in U.S. healthcare infrastructure by tying long-term capital deployment directly to...

Barclays Initiates Coverage On Becton Dickinson with Underweight Rating, Announces Price Target of $165

Barclays analyst Christopher Pasquale initiates coverage on Becton Dickinson (NYSE:BDX) with a Underweight rating and announces Price Target of $165.

Benzinga·10:55BDX▼−0.7%

BDX Expands U.S. Manufacturing With $19B Healthcare Investment

BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.

Yahoo·10:55BDX▼−0.7%

Becton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing

Becton, Dickinson and Company (NYSE:BDX), a global medical technology firm and the largest domestic producer of critical medical consumables, on Tuesday announced a monumental partnership with the U.S. government. The agreement aims to drastically expand domestic manufacturing and fortify the supply chain for vital medical products that patients and clinicians rely on daily. Massive Investment in Domestic Production The strategic alliance directly supports the Trump administration’s ongoing init

Yahoo·12:30BDX▼−0.7%

Trump says Becton Dickinson to invest $3 billion in US medical manufacturing

Investing.com -- Becton Dickinson and Co (NYSE:BDX) has agreed to invest $3 billion to expand U.S. manufacturing of essential medical products, President Donald Trump said on Tuesday, as his administration pushes companies to bring more healthcare production onshore.

Yahoo·00:52

Becton Dickinson Q3 2026 Earnings Call: Complete Transcript

Becton Dickinson (NYSE:BDX) held its third-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and

Benzinga·02:35BDX▼−0.7%

QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel

QGEN expands its U.S. QIAstat-Dx portfolio with an FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.

Yahoo·08:10

3 Historically Stable Dividend Raisers in Medical Devices Offering Solid Yields With Fortress-Like Growth

Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year. One has raised its dividend for 54 consecutive years and still trades at a rare discount.

Yahoo·09:26

BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today marked 70 years of manufacturing in Sandy, Utah, a key part of the company's U.S. manufacturing network and a critical source of the medical technologies healthcare providers and patients depend on for daily care worldwide.

Yahoo·09:00BDX▼−0.7%

How Big Could BSX Stock's Next Fall Be?

Boston Scientific (BSX) stock has lost more than half its value over the past 12 months, while the S&P 500 returned 18.0%. A subsequent setback occurred in September, when the company said a cyberattack would likely keep it from meeting its guidance. If the wider market turns now, how big could the next fall be, and how long would you wait? The answer depends on how well Boston Scientific is equipped to absorb a broader downturn today.

Yahoo·15:09

Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum

Waters (NYSE:WAT) President and Chief Executive Officer Udit Batra said the company’s second-quarter performance exceeded expectations, supported by broad-based growth in its legacy analytical-science operations and early progress integrating acquired Becton Dickinson businesses. Speaking at a JPMo

Yahoo·17:02BDX▼−0.7%

Arthur Hu to Join BD as Chief Information and Digital Officer

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Arthur (Art) Hu has been named executive vice president and chief information and digital officer, effective September 30.

Yahoo·16:30BDX▼−0.7%

Why Is Becton Dickinson (BDX) Facing Fresh SEC And Litigation Pressure?

Becton Dickinson (NYSE:BDX) reached an SEC cease and desist settlement over past Alaris infusion pump risk disclosures, including a civil penalty and creation of a Fair Fund for investors. Subsidiary C.R. Bard recently faced a plaintiff verdict in Bard PowerPort litigation, with thousands of related product liability cases still pending. The Alaris disclosure settlement and Bard PowerPort verdict both tie into a wider pattern of legal and compliance pressures our research tracks. We have...

Yahoo·06:09BDX▼−0.7%

BDX Deploys Vmax 160 to Advance Intelligent Pharmacy Automation

BD expands U.S. pharmacy automation with Vmax 160 at Fairview to handle complex specialty and refrigerated medications.

Yahoo·11:21BDX▼−0.7%

BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Fairview Health Services has become the first health system in the United States to deploy the BD Vmax 160, a next generation pharmacy automation robot designed to help health systems manage the increasing complexity of specialty therapies and refrigerated medicines in high-volume, centralized outpatient pharmacy operations.

Yahoo·06:50BDX▼−0.7%

Becton Dickinson (BDX) Could Be 1% Overvalued As PREVENT Trial Enrollment Ends

Becton Dickinson (BDX) is in focus after announcing completion of patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first in class option for preventing incisional hernias. See our latest analysis for Becton Dickinson. The PREVENT milestone comes after a series of recent updates around Becton Dickinson, including new quality leadership appointments, conference appearances and a recall-related correction notice. It also comes against a backdrop of a 30 day share...

Yahoo·20:10BDX▼−0.7%

Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks

Becton Dickinson stock has delivered a 25.4% return over the past year, while current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and earnings multiples. Over the last 12 months, Becton Dickinson has returned 25.4%, which puts recent gains in focus when assessing how much upside may remain. Progress on the PREVENT clinical trial can support long term cash flow expectations, while the recent recall of...

Yahoo

Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh

Becton Dickinson (NYSE:BDX) reported completion of patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for prevention of incisional hernias. The large scale study is designed to assess the safety and effectiveness of Phasix Mesh as a prophylactic option in patients undergoing abdominal surgery. Finishing enrollment moves the trial closer to data readout and potential regulatory review for what the company positions as a first of its kind product in this category. The...

Yahoo·08:10BDX▼−0.7%

BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study

BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.

Yahoo·13:23BDX▼−0.7%

Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?

Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.

Yahoo·11:48

What's Going On With Becton Dickinson Stock Wednesday?

FDA alerts Becton Dickinson customers to remove recalled Huons sodium chloride ampules from convenience kits. No injuries reported.

Benzinga·09:29BDX▼−0.7%

FDA Issues Early Alert For High-Risk Issue With Becton Dickinson Convenience Kits; Becton Dickinson Advises Removal Of Recalled Components From Convenience Kits; Warns Against Use Of Sodium Chloride Ampules In Affected Bd Kits

https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-convenience-kit-issue-becton-dickinson

Benzinga·12:26BDX▼−0.7%

BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.

Yahoo·16:30BDX▼−0.7%

Are Wall Street Analysts Predicting Becton, Dickinson and Company Stock Will Climb or Sink?

Becton, Dickinson and Company has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Yahoo·11:49BDX▼−0.7%

WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?

West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.

Yahoo·15:23

Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing

Becton Dickinson’s buy rating is reaffirmed as its clinical portfolio grows, Fitch improves risk, and stock momentum returns—get the latest Wall St view.

SeekingAlpha·10:13BDX▼−0.7%

Medline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products

FDA alerts providers as Medline corrects convenience kits with recalled BD applicators due to sterility and contamination risks.

Benzinga·10:00BDX▼−0.7%

Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins

OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.

Yahoo·08:55

RBC Capital Maintains Sector Perform on Becton Dickinson, Raises Price Target to $190

RBC Capital analyst Kendall Au maintains Becton Dickinson (NYSE:BDX) with a Sector Perform and raises the price target from $180 to $190.

Benzinga·06:53BDX▼−0.7%

BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.

Yahoo·06:50BDX▼−0.7%